Ziprasidone in the treatment of mania in bipolar disorder

Stephen E. Nicolson, Charles B. Nemeroff

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Ziprasidone is an atypical antipsychotic with a unique receptor-binding profile. Currently, ziprasidone is approved by the US Food and Drug Administration for the acute treatment of psychosis in schizophrenia and mania in bipolar disorder. When compared to certain other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect profile, especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose dysregulation. Taken together, these data suggest that ziprasidone may be a first line treatment for patients with bipolar mania. However, ziprasidone is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied. Unstudied areas of particular importance include the efficacy and safety of ziprasidone in the treatment of bipolar depression and relapse prevention of mania as, well as in the subpopulations of pregnant women, the elderly and pediatric patients. The emergence of mania in patients taking ziprasidone is another topic for further study.

Original languageEnglish (US)
Pages (from-to)823-834
Number of pages12
JournalNeuropsychiatric Disease and Treatment
Issue number6
StatePublished - 2007
Externally publishedYes


  • Antipsychotic
  • Bipolar disorder
  • Mania
  • Mood disorder
  • Neuroleptic
  • Ziprasidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Ziprasidone in the treatment of mania in bipolar disorder'. Together they form a unique fingerprint.

Cite this